Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering

Aug 26, 2020

Mustang Bio to Present at the Virtual Fortress Biotech Corporate Access Summit

Aug 17, 2020

Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency

Aug 17, 2020

Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020

Aug 17, 2020

Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Aug 14, 2020

Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020

Aug 12, 2020

Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Aug 10, 2020

Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Aug 10, 2020

Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

Aug 05, 2020

Fortress Biotech Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

Jul 31, 2020
RSS
  • Prev
    • 1...
    • 38
    • 39
    • 40
    • 41
    • 42
    • 43
    • 44
    • 45
    • 46
    • 47
    • ...71
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap